Moderna, often accused of being secretive after failing to reveal, publicly at least, its pipeline of meds, finally did so yesterday with its candidates targeting a host of infectious diseases, I-O and CV diseases.
For the first time, researchers have tested a Zika vaccine in animals that do not have a natural resistance to the virus. The synthetic DNA jab protected 100% of vaccinated animals from Zika infection, brain damage and death.
An NIAID-funded team has discovered a Zika antibody that reduces mother-to-fetus transmission of the virus in pregnant mice. This research could lead to the development of vaccines or other therapeutics against the virus.
The U.S. government’s public health emergency department BARDA could pay out more than $300 million to Japanese pharma Takeda to develop a new vaccine against the Zika virus as new figures suggest billions are now at risk of the disease.